Lightpoint Medical reported on Tuesday the receipt of the CE Mark approval for the launch of the world's first robotic gamma probe SENSEI across hospitals in Europe for intra-operative detection of sentinel lymph nodes as well as cancer metastasis through the lymphatic system.

The company said the SENSEI technology promises more precise, targeted cancer surgery and is applicable across a wide range of major cancer types, including lung, colorectal, stomach, gynecological and prostate cancer.

According to the company, SENSEI locates SPECT radioligands including 99mTc-nanocolloid for sentinel lymph node detection or cancer-targeted drugs for cancer metastasis detection such as 99mTc-PSMA (Prostate Specific Membrane Antigen) in prostate cancer surgery.

In addition, the SENSEI promises accurate real-time cancer detection for robot-assisted cancer surgery. Currently, surgeons have no way to precisely detect cancer intra-operatively. The device was successfully registered with the US FDA in September 2020.